About Thorium Norway AS
Thorium Norway AS was established in 2015 with the goal of developing new industries to meet the growing demand for the element Thorium (Th 232).
With around 150+ private investors, the company has formed a project group focused on creating a significant industrial venture.
Our mission is to transform thorium-containing mining waste from the Fen area and other sources around the world into valuable products for the nuclear power and pharmaceutical industries.
Latest News and Insights
Saga Rare Earth AS and Partners Receive NOK 79 Million for Fen Complex Value Chain
January 7, 2026
Saga Rare Earths and partners awarded NOK 79 million from Grønn Plattform to develop Europe's first sustainable rare ear...
Thorium Norway AS Signs Five-Year radium-228 Sales Agreement with entX Limited
December 16, 2025
Thorium Norway has signed a five-year sales agreement with entX Limited (Australia) for Radium-228, a critical precursor...
Thorium Norway AS Gains Access to 10-Year Thorium Supply
December 12, 2025
Agreement with international partner provides Thorium Norway 10-year thorium supply until Fensfeltet is operational....
Products and Services
Thorium Norway AS, in collaboration with Bilfinger Tebodin Netherlands and Thor Energy AS, has developed a factory concept to produce eight products targeting the nuclear power and pharmaceutical markets.
Our factory is designed to handle approximately 1,200 tons of finished products annually, responsibly managing all low-radioactive materials from the Fen area.
Industry Impact
Our thorium-based research contributes to advancements in nuclear energy technology and medical applications. Through our development work, we aim to improve fuel efficiency and reduce waste in nuclear power generation.
Our focus includes the development of thorium-derived materials for medical applications, particularly in targeted therapies for cancer treatment.
